Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy

Heart

Volumn 91, Issue 2, 2005, Pages 161-165

  Di Napoli, Pericle ^a,b   Taccardi, A A ^b   Barsotti, A ^c  

^a Dipartimento di Cardiologia UTIC   (Italy)

^b Department of Cardiology   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; TRIMETAZIDINE;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; LONG-TERM CARE; MALE; PILOT PROJECTS; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 12744261465     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.031310     Document Type: Article

References (21)

1. Sellier P. Chronic effects of trimetazidine on ergometric parameters in effort angina. Cardiovasc Drug Ther 1990;4:822-3.
2. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994;37:279-88.
3. Kantor PF, Lucine A, Kozak R, et al. The anti-anginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8.
4. Allibardi S, Chierchia SL, Margonato V, et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat heart. Cardiovasc Drug Ther 1998;12:543-9.
5. De Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischemia-reperfusion syndrome. Eur Heart J 1993;14(suppl G):34-40.
6. Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle of monocrotaline-treated rats. Biochem Pharmacol 1988;24:4685-8.
7. Brottier L, Barat L, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990;11:207-12.
8. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J 2001;22:2164-70.
9. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
11. Maseri A. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. N Engl J Med 1997;336:1014-6.
12. Fragasso G, Piatti PM, Monti L, et al. Short and long-term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J 2003;146:E1-8.
13. Rosano GM, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diatetol 2003;2:16.
14. Renaud JF. Internal pH, Na+ and Ca++ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drug Ther 1988;1:677-86.
15. Ferrari R, Pepi P, Ferrari F, et al. Metabolic derangement in ischemic heart disease and its therapeutic control. Am J Cardiol 1998;82:2K-13K.
16. Abbate A, Bussani R, Biondi-Zoccai GG, et al. Persistent infarct-related artery occlusion is associated with an increased myocardial apoptosis at post-mortem examination in humans late after an acute myocardial infarction. Circulation 2002;106:1051-4.
17. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied myocardium. Pharmacology 1993;46:324-31.
18. Lu C, Dabrowski P, Fracasso G, et al. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease: a double-blind, placebo-controlled, crossover study. Am J Cardiol 1998;82:898-901.
19. Berton G, Cordiano R, Palmieri R, et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J 2003;145:1094-101.
20. Alonsa-Marrinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002;4:331-6.
21. Williams FM, Tanda K, Kus M, et al. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993;22:828-33.